These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12810298)

  • 1. Expandable gastroretentive dosage forms.
    Klausner EA; Lavy E; Friedman M; Hoffman A
    J Control Release; 2003 Jun; 90(2):143-62. PubMed ID: 12810298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs.
    Klausner EA; Lavy E; Stepensky D; Friedman M; Hoffman A
    Pharm Res; 2002 Oct; 19(10):1516-23. PubMed ID: 12425470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans.
    Klausner EA; Lavy E; Barta M; Cserepes E; Friedman M; Hoffman A
    Pharm Res; 2003 Sep; 20(9):1466-73. PubMed ID: 14567643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview on Various Approaches and Recent Patents on Gastroretentive Drug Delivery Systems.
    Kumar M; Kaushik D
    Recent Pat Drug Deliv Formul; 2018; 12(2):84-92. PubMed ID: 29521255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms.
    Hoffman A; Stepensky D; Lavy E; Eyal S; Klausner E; Friedman M
    Int J Pharm; 2004 Jun; 277(1-2):141-53. PubMed ID: 15158977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroretentive dosage forms.
    Moës AJ
    Crit Rev Ther Drug Carrier Syst; 1993; 10(2):143-95. PubMed ID: 8370085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroretentive dosage forms: overview and special case of Helicobacter pylori.
    Bardonnet PL; Faivre V; Pugh WJ; Piffaretti JC; Falson F
    J Control Release; 2006 Mar; 111(1-2):1-18. PubMed ID: 16403588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems.
    Pawar VK; Kansal S; Garg G; Awasthi R; Singodia D; Kulkarni GT
    Drug Deliv; 2011 Feb; 18(2):97-110. PubMed ID: 20958237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric retentive dosage forms: a review.
    Hou SY; Cowles VE; Berner B
    Crit Rev Ther Drug Carrier Syst; 2003; 20(6):459-97. PubMed ID: 14979868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview on gastroretentive drug delivery systems for improving drug bioavailability.
    Lopes CM; Bettencourt C; Rossi A; Buttini F; Barata P
    Int J Pharm; 2016 Aug; 510(1):144-58. PubMed ID: 27173823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Postprandial Intragastric Pressures on Drug Release from Gastroretentive Dosage Forms.
    Schneider F; Hoppe M; Koziolek M; Weitschies W
    AAPS PharmSciTech; 2018 Oct; 19(7):2843-2850. PubMed ID: 29845498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gastroretentive dosage forms].
    Kiss D; Zelkó R
    Acta Pharm Hung; 2005; 75(3):169-76. PubMed ID: 16318241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs.
    Klausner EA; Eyal S; Lavy E; Friedman M; Hoffman A
    J Control Release; 2003 Feb; 88(1):117-26. PubMed ID: 12586509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Process Optimization for the Continuous Production of a Gastroretentive Dosage Form Based on Melt Foaming.
    Haimhoffer Á; Vasvári G; Trencsényi G; Béresová M; Budai I; Czomba Z; Rusznyák Á; Váradi J; Bácskay I; Ujhelyi Z; Fehér P; Vecsernyés M; Fenyvesi F
    AAPS PharmSciTech; 2021 Jun; 22(5):187. PubMed ID: 34155595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroretentive floating drug-delivery systems: a critical review.
    Kotreka UK; Adeyeye MC
    Crit Rev Ther Drug Carrier Syst; 2011; 28(1):47-99. PubMed ID: 21395515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation and characterization of an expandable, gastroretentive system of carvedilol phosphate by 32 factorial design.
    Avachat AM; Patel KB; Rokade MS; Dash RR
    PDA J Pharm Sci Technol; 2011; 65(1):12-9. PubMed ID: 21414936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Floating dosage systems in drug delivery.
    Reddy LH; Murthy RS
    Crit Rev Ther Drug Carrier Syst; 2002; 19(6):553-85. PubMed ID: 12822735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mechanical antrum model for the prediction of the gastroretentive potential of dosage forms.
    Neumann M; Schneider F; Koziolek M; Garbacz G; Weitschies W
    Int J Pharm; 2017 Sep; 530(1-2):63-70. PubMed ID: 28750896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: where do we stand?
    Awasthi R; Kulkarni GT
    Drug Deliv; 2016; 23(2):378-94. PubMed ID: 25026414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Pulsincap to provide regional delivery of dofetilide to the human GI tract.
    Stevens HN; Wilson CG; Welling PG; Bakhshaee M; Binns JS; Perkins AC; Frier M; Blackshaw EP; Frame MW; Nichols DJ; Humphrey MJ; Wicks SR
    Int J Pharm; 2002 Apr; 236(1-2):27-34. PubMed ID: 11891067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.